



Clinical trial results:

A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix) at an end of shelf-life potency compared to Merck & Co., Inc.'s MMR vaccine (M-M-R II), when both are co-administered with Varivax, Havrix and Prevnar 13 (subset of children), and given on a two-dose schedule to healthy children in their second year of life

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2011-004905-26 |
| Trial protocol | FI CZ ES |
| Global end of trial date | 18 August 2015 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v2 (current) |
| This version publication date | 04 August 2018 |
| First version publication date | 15 January 2017 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 115649 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01681992 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Disclosure Advisor, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 14 September 2016 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 18 August 2015 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

1. To demonstrate non-inferiority of Inv_MMR_Min vaccine compared to pooled Com_MMR vaccine in terms of seroresponse rates & GMCs for antibodies to MMR viruses at Day 42. 2. To demonstrate an acceptable immune response of Inv_MMR_Min & Inv_MMR_Med vaccine in terms of seroresponse rates for MMR viruses at Day 42. 3. To demonstrate non-inferiority of Inv_MMR_Min vaccine compared to pooled Com_MMR vaccine in terms of seroresponse rates & GMTs for antibodies to mumps virus (by PRNT) at Day 42. 4. To demonstrate non-inferiority of Inv_MMR_Med vaccine compared to pooled Com_MMR vaccine in terms of seroresponse rates & GMCs for antibodies to MMR viruses at Day 42. 5. To demonstrate non-inferiority of Inv_MMR_Med vaccine compared to pooled Com_MMR vaccine in terms of seroresponse rates & GMTs for antibodies to mumps virus (by PRNT) at Day 42.

Protection of trial subjects:

All subjects were observed closely for at least 30 minutes following the administration of vaccines with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 10 October 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Czech Republic: 700 |
| Country: Number of subjects enrolled | Finland: 421 |
| Country: Number of subjects enrolled | Malaysia: 134 |
| Country: Number of subjects enrolled | Spain: 1300 |
| Country: Number of subjects enrolled | Thailand: 966 |
| Country: Number of subjects enrolled | United States: 1017 |
| Worldwide total number of subjects | 4538 |
| EEA total number of subjects | 2421 |

Notes:

| Subjects enrolled per age group | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 4538 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

US sub-cohort: Subjects recruited in US and received Inv_MMR_Min or Inv_MMR_Med or Com_MMR (Lot 1 or 2) co-administered with Varivax (VV), Havrix (HAV) and Prevnar 13 (PCV-13) at Day 0. Non-US sub-cohort: Subjects recruited outside US and received Inv_MMR_Min or Inv_MMR_Med or Com_MMR (Lot 1 or 2) co-administered with VV and HAV at Day 0.

Pre-assignment

Screening details:

4538 subjects were registered in the study. 3 subjects were excluded because of invalid Informed Consent Forms and 19 subjects received a subject number but were not vaccinated. Therefore, the number of subjects started is 4516.

Pre-assignment period milestones

| | |
|------------------------------|------|
| Number of subjects started | 4538 |
| Number of subjects completed | 4516 |

Pre-assignment subject non-completion reasons

| | |
|----------------------------|---|
| Reason: Number of subjects | Subject number allocated but not vaccinated: 19 |
| Reason: Number of subjects | Invalid Informed Consent Forms: 3 |

Period 1

| | |
|------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind ^[1] |
| Roles blinded | Subject, Monitor, Data analyst, Carer, Assessor |

Blinding implementation details:

The study was conducted in a double-blind fashion with regard to the two Inv_MMR vaccine lots (Inv_MMR_Min and Inv_MMR_Med) and in an observer-blind fashion for the lots of Inv_MMR vaccine versus the pooled Com_MMR vaccine lots. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint were all unaware of which vaccine was administered.

Arms

| | |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Inv_MMR_Min Group |

Arm description:

Subjects received one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Priorix |
| Investigational medicinal product code | |
| Other name | GSK Biologicals' live attenuated measles, mumps, rubella vaccine |
| Pharmaceutical forms | Powder and solvent for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects received one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.

| | |
|--|---|
| Investigational medicinal product name | Varivax |
| Investigational medicinal product code | |
| Other name | Merck & Co., Inc.'s varicella virus vaccine, live |
| Pharmaceutical forms | Powder and solvent for solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects received one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.

| | |
|--|---|
| Investigational medicinal product name | Havrix |
| Investigational medicinal product code | |
| Other name | GSK Biologicals' hepatitis A vaccine, inactivated |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.

| | |
|--|--|
| Investigational medicinal product name | Prevnar 13 |
| Investigational medicinal product code | |
| Other name | Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

US Subjects received one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.

| | |
|------------------|-------------------|
| Arm title | Inv_MMR_Med Group |
|------------------|-------------------|

Arm description:

Subjects received one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Priorix |
| Investigational medicinal product code | |
| Other name | GSK Biologicals' live attenuated measles, mumps, rubella vaccine |
| Pharmaceutical forms | Powder and solvent for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects received one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.

| | |
|--|---|
| Investigational medicinal product name | Havrix |
| Investigational medicinal product code | |
| Other name | GSK Biologicals' hepatitis A vaccine, inactivated |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.

| | |
|--|--|
| Investigational medicinal product name | Pevnar 13 |
| Investigational medicinal product code | |
| Other name | Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

US Subjects received one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.

| | |
|--|---|
| Investigational medicinal product name | Varivax |
| Investigational medicinal product code | |
| Other name | Merck & Co., Inc.'s varicella virus vaccine, live |
| Pharmaceutical forms | Powder and solvent for solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects received one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.

| | |
|------------------|---------------|
| Arm title | Com_MMR Group |
|------------------|---------------|

Arm description:

Subjects received one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Pevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | M-M-R II |
| Investigational medicinal product code | |
| Other name | Merck & Co., Inc.'s measles, mumps, rubella virus vaccine, live |
| Pharmaceutical forms | Powder and solvent for suspension for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects received two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.

| | |
|--|---|
| Investigational medicinal product name | Varivax |
| Investigational medicinal product code | |
| Other name | Merck & Co., Inc.'s varicella virus vaccine, live |
| Pharmaceutical forms | Powder and solvent for solution for injection in pre-filled syringe |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Subjects received one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.

| | |
|--|---|
| Investigational medicinal product name | Havrix |
| Investigational medicinal product code | |
| Other name | GSK Biologicals' hepatitis A vaccine, inactivated |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.

| | |
|--|--|
| Investigational medicinal product name | Prevnar 13 |
| Investigational medicinal product code | |
| Other name | Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

US Subjects received one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.

Notes:

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: The study was conducted in a double-blind fashion with regard to the two Inv_MMR vaccine lots (Inv_MMR_Min and Inv_MMR_Med) and in an observer-blind fashion for the lots of Inv_MMR vaccine versus the pooled Com_MMR vaccine lots.

| Number of subjects in period 1^[2] | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group |
|---|-------------------|-------------------|---------------|
| Started | 1493 | 1497 | 1526 |
| Completed | 1427 | 1427 | 1443 |
| Not completed | 66 | 70 | 83 |
| Consent withdrawn by subject | 27 | 30 | 25 |
| Adverse event, non-fatal | 3 | 2 | 3 |
| As Per Sponsor Decision | - | - | 1 |
| Lost to follow-up | 36 | 38 | 53 |
| Protocol deviation | - | - | 1 |

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 4538 subjects were registered in the study. 3 subjects were excluded because of invalid Informed Consent Forms and 19 subjects received a subject number but were not vaccinated. Therefore, the number of subjects started is 4516.

Baseline characteristics

Reporting groups

| | |
|-----------------------|-------------------|
| Reporting group title | Inv_MMR_Min Group |
|-----------------------|-------------------|

Reporting group description:

Subjects received one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| | |
|-----------------------|-------------------|
| Reporting group title | Inv_MMR_Med Group |
|-----------------------|-------------------|

Reporting group description:

Subjects received one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| | |
|-----------------------|---------------|
| Reporting group title | Com_MMR Group |
|-----------------------|---------------|

Reporting group description:

Subjects received one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| Reporting group values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group |
|------------------------|-------------------|-------------------|---------------|
| Number of subjects | 1493 | 1497 | 1526 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--------------------------------------|-------|-------|-------|
| Age continuous | | | |
| Units: months | | | |
| arithmetic mean | 12.6 | 12.6 | 12.6 |
| standard deviation | ± 0.9 | ± 0.9 | ± 0.9 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 704 | 718 | 758 |
| Male | 789 | 779 | 768 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| African Heritage / African American | 45 | 53 | 46 |
| American Indian or Alaskan Native | 2 | 1 | 1 |
| Asian - Central/South Asian Heritage | 1 | 0 | 2 |
| Asian - East Asian Heritage | 3 | 0 | 1 |
| Asian - South East Asian Heritage | 362 | 366 | 367 |

| | | | |
|---|------|------|------|
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 |
| White - Arabic / North African Heritage | 8 | 8 | 8 |
| White - Caucasian / European Heritage | 1017 | 1022 | 1052 |
| Other | 55 | 46 | 49 |

| | | | |
|-------------------------------|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 4516 | | |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|------|--|--|
| Age continuous | | | |
| Units: months | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 2180 | | |
| Male | 2336 | | |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| African Heritage / African American | 144 | | |
| American Indian or Alaskan Native | 4 | | |
| Asian - Central/South Asian Heritage | 3 | | |
| Asian - East Asian Heritage | 4 | | |
| Asian - South East Asian Heritage | 1095 | | |
| Native Hawaiian or Other Pacific Islander | 1 | | |
| White - Arabic / North African Heritage | 24 | | |
| White - Caucasian / European Heritage | 3091 | | |
| Other | 150 | | |

End points

End points reporting groups

| | |
|---|-------------------|
| Reporting group title | Inv_MMR_Min Group |
| Reporting group description: Subjects received one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively. | |
| Reporting group title | Inv_MMR_Med Group |
| Reporting group description: Subjects received one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively. | |
| Reporting group title | Com_MMR Group |
| Reporting group description: Subjects received one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects were also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively. | |

Primary: Percentage of subjects with anti-measles virus antibody concentration equal to or above the cut-off-value (by enzyme-linked immunosorbent assay [ELISA])

| | |
|---|--|
| End point title | Percentage of subjects with anti-measles virus antibody concentration equal to or above the cut-off-value (by enzyme-linked immunosorbent assay [ELISA]) |
| End point description: For measles virus, a seroresponse was defined as post-vaccination anti-measles virus antibody concentration equal or above [\geq] 200 mIU/mL (ELISA) among subjects who were seronegative (antibody concentration less than [$<$] 150 mIU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for measles virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be \geq 90% for antibodies to measles virus. | |
| End point type | Primary |
| End point timeframe: At Day 42 | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|------------------------------------|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1361 | 1366 | 1378 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 97.5%) | | | | |
| Anti-measles \geq 150 mIU/mL | 90.9 (89.0 to 92.6) | 94.3 (92.7 to 95.6) | 96.5 (95.2 to 97.5) | |
| Anti-measles \geq 200 mIU/mL | 90.8 (88.9 to 92.5) | 94.2 (92.6 to 95.5) | 96.3 (95.0 to 97.3) | |

Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|--|-----------------------------------|
| Statistical analysis description: | |
| Non-inferiority of Inv_MMR_Min vaccine compared to Com_MMR vaccine in terms of seroresponse rate to measles virus at Day 42. | |
| Comparison groups | Inv_MMR_Min Group v Com_MMR Group |
| Number of subjects included in analysis | 2739 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[1] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -5.48 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -7.65 |
| upper limit | -3.43 |

Notes:

[1] - The lower limit of the 2-sided 97.5% confidence interval (CI) on the group difference (Inv_MMR_Min minus Com_MMR) in seroresponse rate should be \geq -5% for antibodies to measles virus when tested with ELISA.

| Statistical analysis title | Statistical analysis 2 |
|--|-----------------------------------|
| Statistical analysis description: | |
| Non-inferiority of Inv_MMR_Med vaccine compared to Com_MMR vaccine in terms of seroresponse rate to measles virus at Day 42. | |
| Comparison groups | Com_MMR Group v Inv_MMR_Med Group |
| Number of subjects included in analysis | 2744 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[2] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -2.08 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -3.96 |
| upper limit | -0.27 |

Notes:

[2] - The lower limit of the 2-sided 97.5% confidence interval (CI) on the group difference (Inv_MMR_Med minus Com_MMR) in seroresponse rate should be \geq -5% for antibodies to measles virus when tested with ELISA.

Primary: Percentage of subjects with anti-mumps virus antibody concentration equal to or above the cut-off-value (by ELISA)

| | |
|-----------------|--|
| End point title | Percentage of subjects with anti-mumps virus antibody concentration equal to or above the cut-off-value (by ELISA) |
|-----------------|--|

End point description:

For mumps virus, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥ 10 EU/mL (ELISA) among subjects who were seronegative (antibody concentration < 5 EU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for mumps virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be $\geq 90\%$ for antibodies to mumps virus.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Day 42

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|------------------------------------|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1161 | 1131 | 1155 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 97.5%) | | | | |
| Anti-mumps ≥ 5 EU/mL | 99.1 (98.2 to 99.6) | 99.0 (98.1 to 99.6) | 99.2 (98.4 to 99.7) | |
| Anti-mumps ≥ 10 EU/mL | 97.4 (96.2 to 98.3) | 97.3 (96.0 to 98.2) | 97.8 (96.7 to 98.7) | |

Statistical analyses

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical analysis 2 |
|-----------------------------------|------------------------|

Statistical analysis description:

Non-inferiority of Inv_MMR_Med vaccine compared to Com_MMR vaccine in terms of seroresponse rate to mumps virus at Day 42.

| | |
|---|-----------------------------------|
| Comparison groups | Com_MMR Group v Inv_MMR_Med Group |
| Number of subjects included in analysis | 2286 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[3] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -0.58 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -2.11 |
| upper limit | 0.91 |

Notes:

[3] - The lower limit of the 2-sided 97.5% CI on the group difference (Inv_MMR_Med minus Com_MMR) in seroresponse rate should be $\geq -5\%$ for antibodies to mumps virus when tested with ELISA.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical analysis 1 |
|-----------------------------------|------------------------|

Statistical analysis description:

Non-inferiority of Inv_MMR_Min vaccine compared to Com_MMR vaccine in terms of seroresponse rate

to mumps virus at Day 42.

| | |
|---|-----------------------------------|
| Comparison groups | Com_MMR Group v Inv_MMR_Min Group |
| Number of subjects included in analysis | 2316 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[4] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -0.42 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -1.91 |
| upper limit | 1.04 |

Notes:

[4] - The lower limit of the 2-sided 97.5% CI on the group difference (Inv_MMR_Min minus Com_MMR) in seroresponse rate should be $\geq -5\%$ for antibodies to mumps virus when tested with ELISA.

Primary: Percentage of subjects with anti-mumps virus antibody concentration equal to or above the cut-off-value (by Plaque Reduction Neutralization Test [PRNT])

| | |
|-----------------|--|
| End point title | Percentage of subjects with anti-mumps virus antibody concentration equal to or above the cut-off-value (by Plaque Reduction Neutralization Test [PRNT]) |
|-----------------|--|

End point description:

For mumps virus as measured by PRNT, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥ 4 End point Dilution 50% (ED50) (PRNT) among subjects who were seronegative (antibody concentration < 2.5 ED50) before dose 1.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Day 42

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|----------------------------------|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1252 | 1265 | 1287 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| ≥ 2.5 ED50 | 79.1 (76.7 to 81.3) | 81.6 (79.3 to 83.7) | 87.5 (85.6 to 89.2) | |
| ≥ 4 ED50 | 71.2 (68.6 to 73.7) | 73.4 (70.8 to 75.8) | 80.6 (78.3 to 82.7) | |

Statistical analyses

| | |
|----------------------------|------------------------|
| Statistical analysis title | Statistical analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Non-inferiority of Inv_MMR_Min vaccine compared to Com_MMR vaccine in terms of seroresponse rate to mumps virus at Day 42.

| | |
|-------------------|-----------------------------------|
| Comparison groups | Inv_MMR_Min Group v Com_MMR Group |
|-------------------|-----------------------------------|

| | |
|---|---------------------------------|
| Number of subjects included in analysis | 2539 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[5] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -9.41 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -13.2 |
| upper limit | -5.62 |

Notes:

[5] - The lower limit of the 2-sided 97.5% CI on the group difference (Inv_MMR_Min minus Com_MMR) in seroresponse rate should be $\geq -10\%$ for antibodies to mumps virus when tested with PRNT.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical analysis 2 |
|-----------------------------------|------------------------|

Statistical analysis description:

Non-inferiority of Inv_MMR_Med vaccine compared to Com_MMR vaccine in terms of seroresponse rate to mumps virus at Day 42.

| | |
|---|-----------------------------------|
| Comparison groups | Inv_MMR_Med Group v Com_MMR Group |
| Number of subjects included in analysis | 2552 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[6] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -7.22 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -10.94 |
| upper limit | -3.49 |

Notes:

[6] - The lower limit of the 2-sided 97.5% CI on the group difference (Inv_MMR_Med minus Com_MMR) in seroresponse rate should be $\geq -10\%$ for antibodies to mumps virus when tested with PRNT.

Primary: Percentage of subjects with anti-rubella virus antibody concentration equal to or above the cut-off-value (by ELISA)

| | |
|-----------------|--|
| End point title | Percentage of subjects with anti-rubella virus antibody concentration equal to or above the cut-off-value (by ELISA) |
|-----------------|--|

End point description:

For rubella virus, a seroresponse was defined as post-vaccination anti-rubella virus antibody concentration ≥ 10 IU/mL (ELISA) among subjects who were seronegative (antibody concentration < 4 IU/mL) before dose 1. Criteria to demonstrate an acceptable immune response of Inv_MMR_Min/Inv_MMR_Med vaccine in terms of seroresponse rate for rubella virus at Day 42: The lower limit of the two-sided 97.5% CI for the seroresponse rate of Inv_MMR_Min/Inv_MMR_Med was to be $\geq 90\%$ for antibodies to mumps virus.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At Day 42

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|------------------------------------|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1359 | 1366 | 1376 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 97.5%) | | | | |
| ≥ 4 IU/mL | 99.3 (98.6 to 99.7) | 99.5 (98.9 to 99.8) | 99.5 (98.9 to 99.8) | |
| ≥ 10 IU/mL | 96.8 (95.5 to 97.7) | 97.3 (96.1 to 98.2) | 98.5 (97.6 to 99.1) | |

Statistical analyses

| Statistical analysis title | Statistical analysis 2 |
|--|-----------------------------------|
| Statistical analysis description: | |
| Non-inferiority of Inv_MMR_Med vaccine compared to Com_MMR vaccine in terms of seroresponse rate to rubella virus at Day 42. | |
| Comparison groups | Com_MMR Group v Inv_MMR_Med Group |
| Number of subjects included in analysis | 2742 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[7] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -1.18 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -2.5 |
| upper limit | 0.05 |

Notes:

[7] - The lower limit of the 2-sided 97.5% CI on the group difference (Inv_MMR_Med minus Com_MMR) in seroresponse rate should be $\geq -5\%$ for antibodies to rubella virus when tested with ELISA.

| Statistical analysis title | Statistical analysis 1 |
|--|-----------------------------------|
| Statistical analysis description: | |
| Non-inferiority of Inv_MMR_Min vaccine compared to Com_MMR vaccine in terms of seroresponse rate to rubella virus at Day 42. | |
| Comparison groups | Com_MMR Group v Inv_MMR_Min Group |
| Number of subjects included in analysis | 2735 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[8] |
| Parameter estimate | Difference in seroresponse rate |
| Point estimate | -1.71 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | -3.11 |
| upper limit | -0.42 |

Notes:

[8] - The lower limit of the 2-sided 97.5% CI on the group difference (Inv_MMR_Min minus Com_MMR) in seroresponse rate should be $\geq -5\%$ for antibodies to rubella virus when tested with ELISA.

Primary: Anti-measles virus antibody concentrations (by ELISA)

| | |
|------------------------|---|
| End point title | Anti-measles virus antibody concentrations (by ELISA) |
| End point description: | Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) in mIU/mL. |
| End point type | Primary |
| End point timeframe: | At Day 42 |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|--|---------------------------|---------------------------|---------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1361 | 1366 | 1378 | |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 97.5%) | | | | |
| mIU/mL | 2209.9 (2041.3 to 2392.4) | 2540.9 (2368.8 to 2725.5) | 2787.7 (2619.5 to 2966.7) | |

Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|---|--|
| Statistical analysis description: | Non-inferiority of Inv_MMR_Min vaccine compared to COM_MMR vaccine in terms of GMCs for anti-measles antibodies at Day 42. |
| Comparison groups | Com_MMR Group v Inv_MMR_Min Group |
| Number of subjects included in analysis | 2739 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[9] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMC ratio |
| Point estimate | 0.79 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.72 |
| upper limit | 0.88 |

Notes:

[9] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Min over pooled Com_MMR) should to be ≥ 0.67 for antibodies to measles virus when tested with ELISA.

| Statistical analysis title | Statistical analysis 2 |
|-----------------------------------|--|
| Statistical analysis description: | Non-inferiority of Inv_MMR_Med vaccine compared to COM_MMR vaccine in terms of GMCs for anti-measles antibodies at Day 42. |
| Comparison groups | Inv_MMR_Med Group v Com_MMR Group |

| | |
|---|---------------------------------|
| Number of subjects included in analysis | 2744 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[10] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMC ratio |
| Point estimate | 0.91 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.83 |
| upper limit | 1.01 |

Notes:

[10] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Med over pooled Com_MMR) should to be ≥ 0.67 for antibodies to measles virus when tested with ELISA.

Primary: Anti-mumps virus antibody concentrations (by ELISA)

| | |
|--|---|
| End point title | Anti-mumps virus antibody concentrations (by ELISA) |
| End point description: | |
| Antibody concentrations were expressed as GMCs in EU/mL. | |
| End point type | Primary |
| End point timeframe: | |
| At Day 42 | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|--|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1161 | 1131 | 1155 | |
| Units: EU/mL | | | | |
| geometric mean (confidence interval 97.5%) | | | | |
| EU/mL | 58.7 (55.5 to 62.1) | 60.2 (56.8 to 63.7) | 71.6 (67.7 to 75.8) | |

Statistical analyses

| | |
|--|-----------------------------------|
| Statistical analysis title | Statistical analysis 2 |
| Statistical analysis description: | |
| Non-inferiority of Inv_MMR_Med vaccine compared to COM_MMR vaccine in terms of GMCs for anti-mumps antibodies at Day 42. | |
| Comparison groups | Inv_MMR_Med Group v Com_MMR Group |
| Number of subjects included in analysis | 2286 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[11] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMC ratio |
| Point estimate | 0.84 |

| | |
|---------------------|---------------|
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.78 |
| upper limit | 0.91 |

Notes:

[11] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Med over pooled Com_MMR) should to be ≥ 0.67 for antibodies to mumps virus when tested with ELISA.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical analysis 1 |
|-----------------------------------|------------------------|

Statistical analysis description:

Non-inferiority of Inv_MMR_Min vaccine compared to COM_MMR vaccine in terms of GMCs for anti-mumps antibodies at Day 42.

| | |
|---|-----------------------------------|
| Comparison groups | Inv_MMR_Min Group v Com_MMR Group |
| Number of subjects included in analysis | 2316 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[12] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMC ratio |
| Point estimate | 0.82 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.76 |
| upper limit | 0.89 |

Notes:

[12] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Min over pooled Com_MMR) should to be ≥ 0.67 for antibodies to mumps virus when tested with ELISA.

Primary: Anti-mumps virus antibody concentrations (by PRNT)

| | |
|---|--|
| End point title | Anti-mumps virus antibody concentrations (by PRNT) |
| End point description: | |
| Antibody concentrations were expressed as Geometric Mean Titers (GMTs). | |
| End point type | Primary |
| End point timeframe: | |
| At Day 42 | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|--|-------------------|--------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1252 | 1265 | 1287 | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Titers | 9.8 (9.0 to 10.6) | 10.7 (9.9 to 11.5) | 16.3 (15.1 to 17.7) | |

Statistical analyses

| | |
|---|-----------------------------------|
| Statistical analysis title | Statistical analysis 2 |
| Statistical analysis description: Non-inferiority of Inv_MMR_Med vaccine compared to COM_MMR vaccine in terms of GMCs for anti-mumps antibodies at Day 42. | |
| Comparison groups | Inv_MMR_Med Group v Com_MMR Group |
| Number of subjects included in analysis | 2552 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[13] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMT ratio |
| Point estimate | 0.65 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.57 |
| upper limit | 0.74 |

Notes:

[13] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Med over pooled Com_MMR) should to be ≥ 0.67 for antibodies to mumps virus when tested with PRNT.

| | |
|---|-----------------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: Non-inferiority of Inv_MMR_Min vaccine compared to COM_MMR vaccine in terms of GMCs for anti-mumps antibodies at Day 42. | |
| Comparison groups | Inv_MMR_Min Group v Com_MMR Group |
| Number of subjects included in analysis | 2539 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[14] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMT ratio |
| Point estimate | 0.6 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.53 |
| upper limit | 0.68 |

Notes:

[14] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Min over pooled Com_MMR) should to be ≥ 0.67 for antibodies to mumps virus when tested with PRNT.

Primary: Anti-rubella virus antibody concentrations (by ELISA)

| | |
|--|---|
| End point title | Anti-rubella virus antibody concentrations (by ELISA) |
| End point description: Antibody concentrations were expressed as GMCs in IU/mL. | |
| End point type | Primary |
| End point timeframe: At Day 42 | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|--|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1359 | 1366 | 1376 | |
| Units: IU/mL | | | | |
| geometric mean (confidence interval 97.5%) | | | | |
| IU/mL | 57.0 (54.1 to 60.0) | 56.9 (54.2 to 59.8) | 64.4 (61.4 to 67.5) | |

Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

Non-inferiority of Inv_MMR_Min vaccine compared to COM_MMR vaccine in terms of GMCs for anti-rubella antibodies at Day 42.

| | |
|---|-----------------------------------|
| Comparison groups | Com_MMR Group v Inv_MMR_Min Group |
| Number of subjects included in analysis | 2735 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[15] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMC ratio |
| Point estimate | 0.89 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.83 |
| upper limit | 0.95 |

Notes:

[15] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Min over pooled Com_MMR) should to be ≥ 0.67 for antibodies to rubella virus when tested with ELISA.

| Statistical analysis title | Statistical analysis 2 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

Non-inferiority of Inv_MMR_Med vaccine compared to COM_MMR vaccine in terms of GMCs for anti-rubella antibodies at Day 42.

| | |
|---|-----------------------------------|
| Comparison groups | Com_MMR Group v Inv_MMR_Med Group |
| Number of subjects included in analysis | 2742 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[16] |
| Method | ANOVA |
| Parameter estimate | Adjusted GMC ratio |
| Point estimate | 0.88 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 0.83 |
| upper limit | 0.95 |

Notes:

[16] - The lower limit of the 2-sided 97.5% CI on the group ratio of GMCs (Inv_MMR_Med over pooled Com_MMR) should to be ≥ 0.67 for antibodies to rubella virus when tested with ELISA.

Secondary: Percentage of subjects with anti-measles virus antibody concentration equal to or above the cut-off-value (by ELISA)

| | |
|---|--|
| End point title | Percentage of subjects with anti-measles virus antibody concentration equal to or above the cut-off-value (by ELISA) |
| End point description: For measles virus, a seroresponse was defined as post-vaccination anti-measles virus antibody concentration ≥ 200 mIU/mL (ELISA) among subjects who were seronegative (antibody concentration < 150 mIU/mL) before dose 1. | |
| End point type | Secondary |
| End point timeframe: At Day 84 | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|----------------------------------|--------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 245 | 258 | 257 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| ≥ 150 mIU/mL | 99.6 (97.7 to 100) | 98.8 (96.6 to 99.8) | 98.8 (96.6 to 99.8) | |
| ≥ 200 mIU/mL | 99.6 (97.7 to 100) | 98.4 (96.1 to 99.6) | 98.4 (96.1 to 99.6) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects with anti-mumps virus antibody concentration equal to or above the cut-off-value (by ELISA)

| | |
|--|--|
| End point title | Percentage of subjects with anti-mumps virus antibody concentration equal to or above the cut-off-value (by ELISA) |
| End point description: For mumps virus, a seroresponse was defined as post-vaccination anti-mumps virus antibody concentration ≥ 10 EU/mL (ELISA) among subjects who were seronegative (antibody concentration < 5 EU/mL) before dose 1. | |
| End point type | Secondary |
| End point timeframe: At Day 84 | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|----------------------------------|---------------------|-------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 216 | 199 | 212 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| ≥ 5 EU/mL | 99.1 (96.7 to 99.9) | 100 (98.2 to 100) | 99.1 (96.6 to 99.9) | |

| | | | | |
|------------|---------------------|-------------------|---------------------|--|
| ≥ 10 EU/mL | 99.1 (96.7 to 99.9) | 100 (98.2 to 100) | 98.6 (95.9 to 99.7) | |
|------------|---------------------|-------------------|---------------------|--|

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects with anti-rubella virus antibody concentration equal to or above the cut-off-value (by ELISA)

| | |
|-----------------|--|
| End point title | Percentage of subjects with anti-rubella virus antibody concentration equal to or above the cut-off-value (by ELISA) |
|-----------------|--|

End point description:

For rubella virus, a seroresponse was defined as post-vaccination anti-rubella virus antibody concentration ≥ 10 IU/mL (ELISA) among subjects who were seronegative (antibody concentration < 4 IU/mL) before dose 1.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 84

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|----------------------------------|--------------------|--------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 245 | 259 | 255 | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| ≥ 4 IU/mL | 100 (98.5 to 100) | 100 (98.6 to 100) | 100 (98.6 to 100) | |
| ≥ 10 IU/mL | 99.6 (97.7 to 100) | 99.6 (97.9 to 100) | 99.6 (97.8 to 100) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-measles virus antibody concentrations (by ELISA)

| | |
|-----------------|---|
| End point title | Anti-measles virus antibody concentrations (by ELISA) |
|-----------------|---|

End point description:

Antibody concentrations were expressed as GMCs in mIU/mL.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 84

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|--|---------------------------|---------------------------|---------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 245 | 258 | 257 | |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| mIU/mL | 4803.5 (4290.4 to 5378.0) | 4557.7 (4061.5 to 5114.4) | 4453.9 (3951.9 to 5019.8) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-mumps virus antibody concentrations (by ELISA)

| | |
|------------------------|--|
| End point title | Anti-mumps virus antibody concentrations (by ELISA) |
| End point description: | Antibody concentrations were expressed as GMCs in EU/mL. |
| End point type | Secondary |
| End point timeframe: | At Day 84 |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|--|---------------------|----------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 216 | 199 | 212 | |
| Units: EU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| EU/mL | 88.9 (80.4 to 98.3) | 94.1 (85.3 to 103.8) | 86.4 (77.4 to 96.5) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Anti-rubella virus antibody concentrations (by ELISA)

| | |
|------------------------|--|
| End point title | Anti-rubella virus antibody concentrations (by ELISA) |
| End point description: | Antibody concentrations were expressed as GMCs in IU/mL. |
| End point type | Secondary |
| End point timeframe: | At Day 84 |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|--|------------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 245 | 259 | 255 | |
| Units: IU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| IU/mL | 112.7 (104.1 to 122.0) | 110.7 (102.9 to 119.1) | 110.9 (101.8 to 120.8) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any solicited local adverse events (AEs) post dose 1

| | |
|--|--|
| End point title | Number of subjects with any solicited local adverse events (AEs) post dose 1 |
| End point description: Assessed solicited local AEs were pain, redness and swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. | |
| End point type | Secondary |
| End point timeframe: During the 4-day (Days 0-3) post-vaccination period | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1453 | 1464 | 1482 | |
| Units: Participants | | | | |
| Any pain | 261 | 262 | 301 | |
| Any redness | 232 | 256 | 286 | |
| Any swelling | 89 | 97 | 122 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any solicited local AEs post dose 2

| | |
|--|---|
| End point title | Number of subjects with any solicited local AEs post dose 2 |
| End point description: Assessed solicited local AEs were pain, redness and swelling. Any = Occurrence of the AE regardless of | |

intensity grade or relation to vaccination.

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| During the 4-day (Days 0-3) post-vaccination period | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1427 | 1440 | 1456 | |
| Units: Participants | | | | |
| Any pain | 170 | 183 | 196 | |
| Any redness | 159 | 196 | 217 | |
| Any swelling | 67 | 91 | 96 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any solicited general AEs post dose 1

| | |
|---|---|
| End point title | Number of subjects with any solicited general AEs post dose 1 |
| End point description: | |
| Assessed solicited general AEs were drowsiness, irritability/fussiness and loss of appetite. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. | |
| End point type | Secondary |
| End point timeframe: | |
| During the 15-day (Days 0-14) post-vaccination period | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|------------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1454 | 1466 | 1486 | |
| Units: Participants | | | | |
| Any drowsiness | 551 | 565 | 582 | |
| Any irritability / fussiness | 749 | 792 | 788 | |
| Any loss of appetite | 570 | 589 | 591 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any fever post dose 1

| | |
|-----------------|--|
| End point title | Number of subjects reporting any fever post dose 1 |
|-----------------|--|

End point description:

Any fever = Fever (axillary) $\geq 38^{\circ}\text{C}$.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 43-day (Days 0-42) post-vaccination period

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1454 | 1466 | 1486 | |
| Units: Participants | | | | |
| Participants | 582 | 617 | 618 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any fever post dose 2

| | |
|-----------------|--|
| End point title | Number of subjects reporting any fever post dose 2 |
|-----------------|--|

End point description:

Any fever = Fever (axillary) $\geq 38^{\circ}\text{C}$.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 43-day (Days 0-42) post-vaccination period

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1426 | 1443 | 1455 | |
| Units: Participants | | | | |
| Participants | 458 | 471 | 499 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any rash post dose 1

| | |
|-----------------|---|
| End point title | Number of subjects reporting any rash post dose 1 |
|-----------------|---|

End point description:

Assessed were any localized or generalized rash, rash with fever, varicella-like rash and measles/rubella-like rash. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| During the 43-day (Days 0-42) post-vaccination period | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|------------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1454 | 1466 | 1486 | |
| Units: Participants | | | | |
| Any localized or generalized | 328 | 322 | 333 | |
| Any with fever | 115 | 133 | 131 | |
| Any varicella like | 57 | 53 | 45 | |
| Any measles/rubella like | 53 | 61 | 68 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any rash post dose 2

| | |
|---|---|
| End point title | Number of subjects reporting any rash post dose 2 |
| End point description: | |
| Assessed were any localized or generalized rash, rash with fever, varicella-like rash and measles/rubella-like rash. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination. | |
| End point type | Secondary |
| End point timeframe: | |
| During the 43-day (Days 0-42) post-vaccination period | |

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|------------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1426 | 1443 | 1455 | |
| Units: Participants | | | | |
| Any localized or generalized | 129 | 150 | 141 | |
| Any with fever | 52 | 63 | 53 | |
| Any varicella like | 0 | 0 | 1 | |
| Any measles/rubella like | 22 | 14 | 14 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any MMR specific solicited general AEs post dose 1

| | |
|-----------------|---|
| End point title | Number of subjects reporting any MMR specific solicited general AEs post dose 1 |
|-----------------|---|

End point description:

Assessed MMR specific solicited general AEs were any suspected signs of meningism including febrile convulsions and parotid/salivary gland swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 43-day (Days 0-42) post-vaccination period

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1454 | 1466 | 1486 | |
| Units: Participants | | | | |
| Any parotid gland swelling | 3 | 2 | 3 | |
| Any febrile convulsion | 3 | 4 | 3 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any MMR specific solicited general AEs post dose 2

| | |
|-----------------|---|
| End point title | Number of subjects reporting any MMR specific solicited general AEs post dose 2 |
|-----------------|---|

End point description:

Assessed MMR specific solicited general AEs were any suspected signs of meningism including febrile convulsions and parotid/salivary gland swelling. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 43-day (Days 0-42) post-vaccination period

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1426 | 1443 | 1455 | |
| Units: Participants | | | | |
| Any parotid gland swelling | 1 | 2 | 0 | |
| Any febrile convulsion | 2 | 6 | 4 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited AES post dose 1

| | |
|-----------------|--|
| End point title | Number of subjects reporting any unsolicited AES post dose 1 |
|-----------------|--|

End point description:

Unsolicited AE was defined as any AE reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 43-day (Days 0-42) post-vaccination period

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1493 | 1497 | 1526 | |
| Units: Participants | | | | |
| Participants | 762 | 794 | 777 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any unsolicited AES post dose 2

| | |
|-----------------|--|
| End point title | Number of subjects reporting any unsolicited AES post dose 2 |
|-----------------|--|

End point description:

Unsolicited AE was defined as any AE reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = Occurrence of the AE regardless of intensity grade or relation to vaccination.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 43-day (Days 0-42) post-vaccination period

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1449 | 1464 | 1483 | |
| Units: Participants | | | | |
| Participants | 667 | 703 | 690 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any AEs of specific interest

| | |
|-----------------|---|
| End point title | Number of subjects reporting any AEs of specific interest |
|-----------------|---|

End point description:

AEs of specific interest included new onset chronic disease (NOCD) (e.g., autoimmune disorders, asthma, type I diabetes, vasculitis, celiac disease, conditions associated with sub-acute or chronic thrombocytopenia and allergies) and AEs prompting emergency room (ER) visits.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 0 through the end of the study (Day 222)

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|-------------------|-------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1493 | 1497 | 1526 | |
| Units: Participants | | | | |
| Any NOCD | 35 | 39 | 33 | |
| Any AE prompting ER visit | 348 | 361 | 347 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any serious adverse events (SAEs)

| | |
|-----------------|--|
| End point title | Number of subjects reporting any serious adverse events (SAEs) |
|-----------------|--|

End point description:

SAEs assessed include any untoward medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 0 through the end of the study (Day 222)

| End point values | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group | |
|-----------------------------|----------------------|----------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 1493 | 1497 | 1526 | |
| Units: Participants | | | | |
| Participants | 91 | 102 | 92 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited local & general AEs: During the 4-day (Days 0-3) and 15-day (Days 0-14) post-vaccination period, respectively; Unsolicited AEs: During the 43-day (Days 0-42) post-vaccination period; SAEs: From Day 0 through the end of the study (Day 222).

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 19.0 |

Reporting groups

| | |
|-----------------------|-------------------|
| Reporting group title | Inv_MMR_Min Group |
|-----------------------|-------------------|

Reporting group description:

Subjects received one dose of Inv_MMR, from a minimum potency lot (Inv_MMR_Min), co-administered with VV and HAV vaccines at Day 0. All US subjects were also co-administered PCV-13 vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| | |
|-----------------------|-------------------|
| Reporting group title | Inv_MMR_Med Group |
|-----------------------|-------------------|

Reporting group description:

Subjects received one dose of Inv_MMR, from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with VV and HAV vaccines at Day 0. All US subjects were also co-administered PCV-13 vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| | |
|-----------------------|---------------|
| Reporting group title | Com_MMR Group |
|-----------------------|---------------|

Reporting group description:

Subjects received one dose of Com_MMR vaccine (Lot 1 or Lot 2), co-administered with VV and HAV vaccines at Day 0. All US subjects were also co-administered PCV-13 vaccine. Approximately 6 weeks later, at Day 42, subjects were administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines were administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines were administered intramuscularly in the anterolateral region of the right and left thigh, respectively.

| Serious adverse events | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group |
|---|-------------------|--------------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 91 / 1493 (6.10%) | 102 / 1497 (6.81%) | 92 / 1526 (6.03%) |
| number of deaths (all causes) | 1 | 0 | 1 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Vascular disorders | | | |
| Circulatory collapse | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|------------------|------------------|------------------|
| Phlebitis superficial | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombophlebitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Drowning | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 4 / 1497 (0.27%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 4 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Allergy to arthropod bite | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Apnoea | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspiration | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Asthma | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atelectasis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchial hyperreactivity | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchospasm | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory distress | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wheezing | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Accidental poisoning | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Burns second degree | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest injury | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Child maltreatment syndrome | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Concussion | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Contusion | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Face injury | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Foreign body | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Head injury | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laceration | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Limb crushing injury | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mouth injury | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple injuries | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Poisoning | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 3 / 1526 (0.20%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxicity to various agents | | | |

| | | | |
|---|------------------|-------------------|------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Burning sensation | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epilepsy | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Febrile convulsion | | | |
| subjects affected / exposed | 7 / 1493 (0.47%) | 13 / 1497 (0.87%) | 8 / 1526 (0.52%) |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 15 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intracranial pressure increased | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|------------------|------------------|------------------|
| Haemolytic anaemia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypochromic anaemia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 3 / 1497 (0.20%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Anal fistula | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 3 / 1497 (0.20%) | 4 / 1526 (0.26%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Food poisoning | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perianal erythema | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Teething | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Liver disorder | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Henoch-schonlein purpura | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Petechiae | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stevens-johnson syndrome | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxic skin eruption | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urticaria | | | |

| | | | |
|--|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Juvenile idiopathic arthritis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Synovitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Adenovirus infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atypical pneumonia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchiolitis | | | |
| subjects affected / exposed | 6 / 1493 (0.40%) | 7 / 1497 (0.47%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 7 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|------------------|-------------------|------------------|
| Bronchitis | | | |
| subjects affected / exposed | 4 / 1493 (0.27%) | 10 / 1497 (0.67%) | 8 / 1526 (0.52%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 10 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis viral | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Campylobacter gastroenteritis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis orbital | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Croup infectious | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 3 / 1497 (0.20%) | 4 / 1526 (0.26%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis klebsiella | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dengue fever | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea infectious | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 3 / 1526 (0.20%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear infection | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Empyema | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Encephalitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Encephalitis brain stem | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterococcal bacteraemia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia urinary tract infection | | | |

| | | | |
|---|-------------------|-------------------|-------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Exanthema subitum | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 16 / 1493 (1.07%) | 19 / 1497 (1.27%) | 10 / 1526 (0.66%) |
| occurrences causally related to treatment / all | 0 / 16 | 0 / 19 | 0 / 10 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis bacterial | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis rotavirus | | | |
| subjects affected / exposed | 6 / 1493 (0.40%) | 3 / 1497 (0.20%) | 7 / 1526 (0.46%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 3 | 0 / 7 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis salmonella | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hand-foot-and-mouth disease | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 2 / 1497 (0.13%) | 4 / 1526 (0.26%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpangina | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 3 / 1526 (0.20%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngitis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 4 / 1526 (0.26%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngotracheitis obstructive | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nail bed infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 3 / 1497 (0.20%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nosocomial infection | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis media | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 3 / 1497 (0.20%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis media acute | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis media viral | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otosalpingitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Periorbital cellulitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngotonsillitis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 5 / 1497 (0.33%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 5 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |

| | | | |
|---|------------------|-------------------|-------------------|
| subjects affected / exposed | 7 / 1493 (0.47%) | 14 / 1497 (0.94%) | 10 / 1526 (0.66%) |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 14 | 0 / 10 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia bacterial | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 2 / 1497 (0.13%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia respiratory syncytial viral | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia viral | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 6 / 1497 (0.40%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 7 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory syncytial virus bronchiolitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory syncytial virus bronchitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory syncytial virus infection | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin candida | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tonsillitis | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 3 / 1497 (0.20%) | 3 / 1526 (0.20%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral pharyngitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral tonsillitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 4 / 1493 (0.27%) | 7 / 1497 (0.47%) | 6 / 1526 (0.39%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 7 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 2 / 1526 (0.13%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Type 1 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Inv_MMR_Min Group | Inv_MMR_Med Group | Com_MMR Group |
|---|----------------------|----------------------|----------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1299 / 1493 (87.01%) | 1311 / 1497 (87.58%) | 1330 / 1526 (87.16%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Brain neoplasm | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haemangioma | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyogenic granuloma | | | |

| | | | |
|--|-----------------------|-----------------------|-----------------------|
| subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Vascular disorders | | | |
| Flushing | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Perinatal brain damage | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Adverse drug reaction | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Application site erythema | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 1 | 2 |
| Application site hypersensitivity | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Crying | | | |
| subjects affected / exposed | 4 / 1493 (0.27%) | 4 / 1497 (0.27%) | 5 / 1526 (0.33%) |
| occurrences (all) | 5 | 4 | 7 |
| Decreased activity | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Fatigue | | | |

| | | | |
|-----------------------------|-------------------|-------------------|------------------|
| subjects affected / exposed | 2 / 1493 (0.13%) | 2 / 1497 (0.13%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 3 | 1 |
| Feeling hot | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 1 | 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 1 | 1 |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 0 | 3 |
| Injection site erythema | | | |
| subjects affected / exposed | 11 / 1493 (0.74%) | 15 / 1497 (1.00%) | 9 / 1526 (0.59%) |
| occurrences (all) | 11 | 15 | 9 |
| Injection site haematoma | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 3 / 1526 (0.20%) |
| occurrences (all) | 0 | 0 | 3 |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 3 / 1497 (0.20%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Injection site induration | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 4 / 1497 (0.27%) | 2 / 1526 (0.13%) |
| occurrences (all) | 2 | 4 | 2 |
| Injection site inflammation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection site mass | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injection site nodule | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site pain | | | |

| | | | |
|-----------------------------|------------------------|------------------------|------------------------|
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 1 | 1 |
| Injection site papule | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Injection site swelling | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 5 / 1497 (0.33%) | 2 / 1526 (0.13%) |
| occurrences (all) | 3 | 5 | 2 |
| Injection site urticaria | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Local swelling | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Malaise | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences (all) | 3 | 3 | 4 |
| Mass | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain | | | |
| subjects affected / exposed | 334 / 1493 (22.37%) | 336 / 1497 (22.44%) | 378 / 1526 (24.77%) |
| occurrences (all) | 431 | 445 | 500 |
| Peripheral swelling | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Swelling | | | |
| subjects affected / exposed | 123 / 1493 (8.24%) | 152 / 1497 (10.15%) | 170 / 1526 (11.14%) |
| occurrences (all) | 156 | 188 | 218 |

| | | | |
|--|-----------------------|-----------------------|-----------------------|
| Vaccination site erythema subjects affected / exposed occurrences (all) | 7 / 1493 (0.47%) 7 | 6 / 1497 (0.40%) 6 | 8 / 1526 (0.52%) 8 |
| Vaccination site haematoma subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Vaccination site pain subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Vaccination site rash subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Vaccination site reaction subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Vaccination site swelling subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 1 / 1497 (0.07%) 1 | 1 / 1526 (0.07%) 1 |
| Vessel puncture site haemorrhage subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Immune system disorders | | | |
| Allergy to animal subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Drug hypersensitivity subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 2 / 1497 (0.13%) 2 | 3 / 1526 (0.20%) 3 |
| Food allergy subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Hypersensitivity subjects affected / exposed occurrences (all) | 2 / 1493 (0.13%) 2 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Milk allergy | | | |

| | | | |
|--|-----------------------|-----------------------|-----------------------|
| subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Multiple allergies subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 1 / 1526 (0.07%) 1 |
| Seasonal allergy subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Reproductive system and breast disorders | | | |
| Balanoposthitis subjects affected / exposed occurrences (all) | 2 / 1493 (0.13%) 2 | 3 / 1497 (0.20%) 3 | 1 / 1526 (0.07%) 2 |
| Genital erythema subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Genital labial adhesions subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Penile adhesion subjects affected / exposed occurrences (all) | 2 / 1493 (0.13%) 2 | 0 / 1497 (0.00%) 0 | 2 / 1526 (0.13%) 2 |
| Penile erythema subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Perineal erythema subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Scrotal swelling subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Testicular pain subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|------------------------------------|-------------------|-------------------|-------------------|
| Asthma | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 5 / 1497 (0.33%) | 3 / 1526 (0.20%) |
| occurrences (all) | 2 | 5 | 3 |
| Bronchial hyperreactivity | | | |
| subjects affected / exposed | 7 / 1493 (0.47%) | 4 / 1497 (0.27%) | 8 / 1526 (0.52%) |
| occurrences (all) | 8 | 5 | 9 |
| Bronchospasm | | | |
| subjects affected / exposed | 7 / 1493 (0.47%) | 3 / 1497 (0.20%) | 2 / 1526 (0.13%) |
| occurrences (all) | 7 | 3 | 2 |
| Catarrh | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences (all) | 1 | 2 | 3 |
| Cough | | | |
| subjects affected / exposed | 59 / 1493 (3.95%) | 64 / 1497 (4.28%) | 75 / 1526 (4.91%) |
| occurrences (all) | 68 | 74 | 84 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 3 / 1497 (0.20%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 4 / 1497 (0.27%) | 2 / 1526 (0.13%) |
| occurrences (all) | 3 | 4 | 2 |
| Lower respiratory tract congestion | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasal congestion | | | |
| subjects affected / exposed | 9 / 1493 (0.60%) | 12 / 1497 (0.80%) | 10 / 1526 (0.66%) |
| occurrences (all) | 9 | 12 | 12 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 3 / 1497 (0.20%) | 3 / 1526 (0.20%) |
| occurrences (all) | 1 | 3 | 6 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------|-------------------|-------------------|-------------------|
| Rhinitis allergic | | | |
| subjects affected / exposed | 4 / 1493 (0.27%) | 0 / 1497 (0.00%) | 6 / 1526 (0.39%) |
| occurrences (all) | 4 | 0 | 6 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 32 / 1493 (2.14%) | 25 / 1497 (1.67%) | 39 / 1526 (2.56%) |
| occurrences (all) | 39 | 33 | 41 |
| Sinus congestion | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Sinus disorder | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 0 | 1 |
| Sleep apnoea syndrome | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sneezing | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 9 / 1497 (0.60%) | 7 / 1526 (0.46%) |
| occurrences (all) | 3 | 9 | 7 |
| Psychiatric disorders | | | |
| Agitation | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Bruxism | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Irritability | | | |

| | | | |
|--------------------------------------|------------------------|------------------------|------------------------|
| subjects affected / exposed | 757 / 1493 (50.70%) | 795 / 1497 (53.11%) | 793 / 1526 (51.97%) |
| occurrences (all) | 781 | 815 | 815 |
| Mood altered | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervousness | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Restlessness | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 0 | 1 |
| Tearfulness | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Product issues | | | |
| Device occlusion | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Investigations | | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Body temperature increased | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Cardiac murmur | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastric ph decreased | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Staphylococcus test positive | | | |

| | | | |
|--|-------------------------|-------------------------|-------------------------|
| subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Accidental exposure to product subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Animal bite subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 2 / 1526 (0.13%) 2 |
| Arthropod bite subjects affected / exposed occurrences (all) | 24 / 1493 (1.61%) 29 | 21 / 1497 (1.40%) 23 | 12 / 1526 (0.79%) 13 |
| Arthropod sting subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 3 | 2 / 1497 (0.13%) 2 | 1 / 1526 (0.07%) 1 |
| Burns second degree subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 3 / 1497 (0.20%) 3 | 1 / 1526 (0.07%) 1 |
| Contusion subjects affected / exposed occurrences (all) | 8 / 1493 (0.54%) 9 | 7 / 1497 (0.47%) 8 | 9 / 1526 (0.59%) 9 |
| Ear canal abrasion subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Excoriation subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 1 / 1526 (0.07%) 1 |
| Exposure to communicable disease subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Exposure to toxic agent subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Eye injury | | | |

| | | | |
|-----------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 2 | 1 |
| Eyelid injury | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 2 | 1 |
| Face injury | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 3 / 1497 (0.20%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Fall | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 4 / 1497 (0.27%) | 7 / 1526 (0.46%) |
| occurrences (all) | 5 | 4 | 8 |
| Foot fracture | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Foreign body | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Head injury | | | |
| subjects affected / exposed | 8 / 1493 (0.54%) | 7 / 1497 (0.47%) | 7 / 1526 (0.46%) |
| occurrences (all) | 8 | 7 | 7 |
| Injury | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 2 / 1497 (0.13%) | 4 / 1526 (0.26%) |
| occurrences (all) | 2 | 2 | 4 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Laceration | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 6 / 1497 (0.40%) | 7 / 1526 (0.46%) |
| occurrences (all) | 3 | 6 | 7 |
| Limb injury | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 1 | 1 |
| Lip injury | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 4 / 1497 (0.27%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 4 | 1 |
| Mouth injury | | | |

| | | | |
|-----------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 1 | 1 |
| Procedural vomiting | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Radial head dislocation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 0 | 2 |
| Radius fracture | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Road traffic accident | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 2 / 1526 (0.13%) |
| occurrences (all) | 1 | 0 | 2 |
| Skin abrasion | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 5 / 1497 (0.33%) | 5 / 1526 (0.33%) |
| occurrences (all) | 2 | 5 | 5 |
| Skin wound | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Thermal burn | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 4 / 1497 (0.27%) | 4 / 1526 (0.26%) |
| occurrences (all) | 2 | 4 | 4 |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Tongue injury | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Tooth fracture | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Tooth injury | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 1 | 2 |
| Vaccination complication | | | |

| | | | |
|--|-----------------------|-------------------------|-----------------------|
| subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 3 / 1497 (0.20%) 3 | 2 / 1526 (0.13%) 2 |
| Wound subjects affected / exposed occurrences (all) | 4 / 1493 (0.27%) 4 | 10 / 1497 (0.67%) 10 | 5 / 1526 (0.33%) 5 |
| Congenital, familial and genetic disorders | | | |
| Dermoid cyst subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Inborn error of metabolism subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Keratosis follicular subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Naevus flammeus subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Phimosis subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 2 / 1497 (0.13%) 2 | 1 / 1526 (0.07%) 1 |
| Talipes subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Cardiac disorders | | | |
| Arrhythmia subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Nervous system disorders | | | |
| Aphonia subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 1 / 1497 (0.07%) 1 | 1 / 1526 (0.07%) 1 |
| Cerebrovascular accident subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Drooling | | | |

| | | | |
|--------------------------------------|------------------------|------------------------|------------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 0 | 1 |
| Headache | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Language disorder | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lethargy | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Poor quality sleep | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Psychomotor hyperactivity | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Sleep phase rhythm disturbance | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Somnolence | | | |
| subjects affected / exposed | 551 / 1493 (36.91%) | 567 / 1497 (37.88%) | 582 / 1526 (38.14%) |
| occurrences (all) | 552 | 569 | 582 |
| Syncope | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tongue biting | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 6 / 1493 (0.40%) | 5 / 1497 (0.33%) | 4 / 1526 (0.26%) |
| occurrences (all) | 6 | 5 | 4 |
| Hypochromic anaemia | | | |

| | | | |
|-------------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 3 / 1497 (0.20%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 3 | 1 |
| Lymphadenitis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences (all) | 2 | 2 | 2 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 8 / 1493 (0.54%) | 5 / 1497 (0.33%) | 2 / 1526 (0.13%) |
| occurrences (all) | 8 | 5 | 2 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ear and labyrinth disorders | | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Ear disorder | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 0 | 1 |
| Ear pain | | | |
| subjects affected / exposed | 6 / 1493 (0.40%) | 7 / 1497 (0.47%) | 6 / 1526 (0.39%) |
| occurrences (all) | 6 | 7 | 6 |
| Middle ear inflammation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Otorrhoea | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 3 / 1526 (0.20%) |
| occurrences (all) | 1 | 1 | 4 |
| Tympanic membrane perforation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 0 | 2 |
| Eye disorders | | | |
| Blepharitis | | | |

| | | | |
|-----------------------------|------------------|------------------|------------------|
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Conjunctival hyperaemia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Conjunctivitis allergic | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Eye discharge | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 2 / 1497 (0.13%) | 3 / 1526 (0.20%) |
| occurrences (all) | 1 | 2 | 3 |
| Eye oedema | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Eye swelling | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eyelid bleeding | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eyelid cyst | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eyelid oedema | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lacrimation increased | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Gastrointestinal disorders | | | |

| | | | |
|--|-------------------------|-------------------------|-------------------------|
| Abdominal discomfort subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 2 / 1497 (0.13%) 2 | 0 / 1526 (0.00%) 0 |
| Abdominal distension subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Abdominal pain subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 3 | 2 / 1497 (0.13%) 3 | 3 / 1526 (0.20%) 3 |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Anal fissure subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 3 | 3 / 1497 (0.20%) 3 | 3 / 1526 (0.20%) 3 |
| Aphthous ulcer subjects affected / exposed occurrences (all) | 6 / 1493 (0.40%) 6 | 7 / 1497 (0.47%) 7 | 3 / 1526 (0.20%) 3 |
| Cheilitis subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Colitis subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 2 / 1497 (0.13%) 2 | 0 / 1526 (0.00%) 0 |
| Constipation subjects affected / exposed occurrences (all) | 11 / 1493 (0.74%) 11 | 11 / 1497 (0.73%) 13 | 6 / 1526 (0.39%) 6 |
| Diarrhoea subjects affected / exposed occurrences (all) | 73 / 1493 (4.89%) 83 | 71 / 1497 (4.74%) 76 | 75 / 1526 (4.91%) 80 |
| Dyspepsia subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 2 / 1497 (0.13%) 2 | 1 / 1526 (0.07%) 1 |
| Enteritis subjects affected / exposed occurrences (all) | 19 / 1493 (1.27%) 19 | 21 / 1497 (1.40%) 23 | 19 / 1526 (1.25%) 20 |

| | | | |
|--------------------------------------|------------------|------------------|------------------|
| Enterocolitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Food poisoning | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 0 | 1 |
| Functional gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastritis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 3 / 1526 (0.20%) |
| occurrences (all) | 2 | 0 | 3 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences (all) | 2 | 2 | 2 |
| Gingival disorder | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Gingival pain | | | |
| subjects affected / exposed | 4 / 1493 (0.27%) | 4 / 1497 (0.27%) | 2 / 1526 (0.13%) |
| occurrences (all) | 5 | 4 | 2 |
| Glossodynia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences (all) | 1 | 1 | 3 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|----------------------------------|------------------|------------------|------------------|
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lip disorder | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Lip ulceration | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Malocclusion | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Mouth ulceration | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences (all) | 1 | 1 | 2 |
| Nausea | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences (all) | 1 | 2 | 2 |
| Noninfective gingivitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Oral disorder | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Palatal ulcer | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Periodontal disease | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Protein-losing gastroenteropathy | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Regurgitation | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |

| | | | |
|--|-------------------------|--------------------------|-------------------------|
| Salivary gland enlargement subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Salivary hypersecretion subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Stomatitis subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 3 | 6 / 1497 (0.40%) 6 | 3 / 1526 (0.20%) 3 |
| Teething subjects affected / exposed occurrences (all) | 62 / 1493 (4.15%) 86 | 71 / 1497 (4.74%) 104 | 64 / 1526 (4.19%) 82 |
| Tongue blistering subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Tooth discolouration subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Tooth disorder subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 4 | 2 / 1497 (0.13%) 2 | 0 / 1526 (0.00%) 0 |
| Toothache subjects affected / exposed occurrences (all) | 22 / 1493 (1.47%) 31 | 17 / 1497 (1.14%) 21 | 17 / 1526 (1.11%) 22 |
| Vomiting subjects affected / exposed occurrences (all) | 43 / 1493 (2.88%) 55 | 42 / 1497 (2.81%) 45 | 48 / 1526 (3.15%) 51 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Angioedema subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Dermal cyst | | | |

| | | | |
|-----------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dermatitis | | | |
| subjects affected / exposed | 9 / 1493 (0.60%) | 9 / 1497 (0.60%) | 17 / 1526 (1.11%) |
| occurrences (all) | 9 | 10 | 17 |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 2 | 1 |
| Dermatitis atopic | | | |
| subjects affected / exposed | 15 / 1493 (1.00%) | 14 / 1497 (0.94%) | 13 / 1526 (0.85%) |
| occurrences (all) | 16 | 16 | 15 |
| Dermatitis contact | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 2 / 1497 (0.13%) | 3 / 1526 (0.20%) |
| occurrences (all) | 3 | 2 | 3 |
| Dermatitis diaper | | | |
| subjects affected / exposed | 12 / 1493 (0.80%) | 18 / 1497 (1.20%) | 21 / 1526 (1.38%) |
| occurrences (all) | 12 | 19 | 21 |
| Ecchymosis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Eczema | | | |
| subjects affected / exposed | 16 / 1493 (1.07%) | 7 / 1497 (0.47%) | 7 / 1526 (0.46%) |
| occurrences (all) | 16 | 7 | 9 |
| Erythema | | | |
| subjects affected / exposed | 288 / 1493 (19.29%) | 331 / 1497 (22.11%) | 362 / 1526 (23.72%) |
| occurrences (all) | 394 | 455 | 505 |
| Erythema multiforme | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ingrowing nail | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Intertrigo | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences (all) | 4 | 2 | 2 |

| | | | |
|-----------------------------|------------------|------------------|------------------|
| Macule | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Miliaria | | | |
| subjects affected / exposed | 6 / 1493 (0.40%) | 4 / 1497 (0.27%) | 4 / 1526 (0.26%) |
| occurrences (all) | 6 | 4 | 4 |
| Nail disorder | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Onychomadesis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 1 | 2 |
| Petechiae | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Prurigo | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 3 / 1497 (0.20%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Rash vesicular | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Seborrhoeic dermatitis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 1 | 1 |

| | | | |
|--|-----------------------|-----------------------|-----------------------|
| Skin burning sensation subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Skin discolouration subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Skin irritation subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 2 / 1526 (0.13%) 2 |
| Skin lesion subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 2 | 0 / 1526 (0.00%) 0 |
| Skin ulcer subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 2 / 1497 (0.13%) 2 | 0 / 1526 (0.00%) 0 |
| Skin warm subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 2 / 1497 (0.13%) 2 | 0 / 1526 (0.00%) 0 |
| Spider naevus subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Swelling face subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Urticaria subjects affected / exposed occurrences (all) | 4 / 1493 (0.27%) 4 | 5 / 1497 (0.33%) 5 | 3 / 1526 (0.20%) 3 |
| Musculoskeletal and connective tissue disorders | | | |
| Foot deformity subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Myalgia subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Neck mass | | | |

| | | | |
|---|-------------------------|-------------------------|-------------------------|
| subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Pain in extremity subjects affected / exposed occurrences (all) | 2 / 1493 (0.13%) 2 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Synovitis subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 4 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Infections and infestations | | | |
| Abscess subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 2 / 1526 (0.13%) 2 |
| Acarodermatitis subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Acute sinusitis subjects affected / exposed occurrences (all) | 2 / 1493 (0.13%) 2 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Adenoiditis subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Adenoviral conjunctivitis subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Adenovirus infection subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Angular cheilitis subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Body tinea subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Bronchiolitis subjects affected / exposed occurrences (all) | 18 / 1493 (1.21%) 22 | 22 / 1497 (1.47%) 22 | 21 / 1526 (1.38%) 22 |

| | | | |
|-------------------------------|-------------------|-------------------|-------------------|
| Bronchitis | | | |
| subjects affected / exposed | 81 / 1493 (5.43%) | 96 / 1497 (6.41%) | 77 / 1526 (5.05%) |
| occurrences (all) | 92 | 115 | 95 |
| Bronchitis viral | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Bullous impetigo | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Burn infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Campylobacter gastroenteritis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 2 | 2 |
| Campylobacter infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Candida infection | | | |
| subjects affected / exposed | 6 / 1493 (0.40%) | 9 / 1497 (0.60%) | 7 / 1526 (0.46%) |
| occurrences (all) | 7 | 9 | 7 |
| Candida nappy rash | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 3 / 1526 (0.20%) |
| occurrences (all) | 0 | 2 | 3 |
| Conjunctivitis | | | |
| subjects affected / exposed | 63 / 1493 (4.22%) | 79 / 1497 (5.28%) | 79 / 1526 (5.18%) |
| occurrences (all) | 67 | 90 | 87 |
| Conjunctivitis bacterial | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Conjunctivitis viral | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|-------------------------|-------------------------|-------------------------|
| Coxsackie viral infection subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 2 / 1526 (0.13%) 2 |
| Croup infectious subjects affected / exposed occurrences (all) | 4 / 1493 (0.27%) 4 | 11 / 1497 (0.73%) 11 | 12 / 1526 (0.79%) 13 |
| Cryptosporidiosis infection subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Cystitis subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Ear infection subjects affected / exposed occurrences (all) | 19 / 1493 (1.27%) 19 | 19 / 1497 (1.27%) 20 | 12 / 1526 (0.79%) 13 |
| Eczema impetiginous subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Enterobiasis subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 2 / 1497 (0.13%) 2 | 0 / 1526 (0.00%) 0 |
| Enterovirus infection subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 3 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Erythema infectiosum subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Exanthema subitum subjects affected / exposed occurrences (all) | 2 / 1493 (0.13%) 2 | 5 / 1497 (0.33%) 5 | 1 / 1526 (0.07%) 1 |
| Eye infection subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Folliculitis subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 3 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |

| | | | |
|-----------------------------|-------------------|-------------------|-------------------|
| Fungal infection | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Fungal skin infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 3 / 1497 (0.20%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastritis viral | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 0 / 1497 (0.00%) | 2 / 1526 (0.13%) |
| occurrences (all) | 4 | 0 | 2 |
| Gastroenteritis | | | |
| subjects affected / exposed | 88 / 1493 (5.89%) | 95 / 1497 (6.35%) | 93 / 1526 (6.09%) |
| occurrences (all) | 93 | 107 | 100 |
| Gastroenteritis norovirus | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 2 / 1497 (0.13%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Gastroenteritis salmonella | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 7 / 1493 (0.47%) | 6 / 1497 (0.40%) | 9 / 1526 (0.59%) |
| occurrences (all) | 7 | 6 | 9 |
| Genital candidiasis | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gingivitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 2 / 1526 (0.13%) |
| occurrences (all) | 0 | 0 | 2 |
| Hand-foot-and-mouth disease | | | |
| subjects affected / exposed | 10 / 1493 (0.67%) | 23 / 1497 (1.54%) | 10 / 1526 (0.66%) |
| occurrences (all) | 10 | 23 | 11 |
| Herpangina | | | |
| subjects affected / exposed | 9 / 1493 (0.60%) | 8 / 1497 (0.53%) | 8 / 1526 (0.52%) |
| occurrences (all) | 9 | 8 | 8 |

| | | | |
|---|-------------------|-------------------|-------------------|
| Herpes virus infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 0 | 1 |
| Hordeolum | | | |
| subjects affected / exposed | 3 / 1493 (0.20%) | 3 / 1497 (0.20%) | 1 / 1526 (0.07%) |
| occurrences (all) | 3 | 3 | 1 |
| Impetigo | | | |
| subjects affected / exposed | 6 / 1493 (0.40%) | 7 / 1497 (0.47%) | 9 / 1526 (0.59%) |
| occurrences (all) | 6 | 7 | 9 |
| Infected bite | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Influenza | | | |
| subjects affected / exposed | 7 / 1493 (0.47%) | 11 / 1497 (0.73%) | 10 / 1526 (0.66%) |
| occurrences (all) | 8 | 13 | 10 |
| Laryngitis | | | |
| subjects affected / exposed | 34 / 1493 (2.28%) | 34 / 1497 (2.27%) | 27 / 1526 (1.77%) |
| occurrences (all) | 35 | 37 | 30 |
| Lice infestation | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 4 / 1497 (0.27%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Localised infection | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 0 | 1 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 4 / 1493 (0.27%) | 4 / 1497 (0.27%) | 5 / 1526 (0.33%) |
| occurrences (all) | 4 | 5 | 5 |
| Lower respiratory tract infection viral | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Mastitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Molluscum contagiosum | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|---|---------------------------|-------------------------------|---------------------------|
| Mycoplasma infection subjects affected / exposed occurrences (all) | 5 / 1493 (0.33%) 5 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 148 / 1493 (9.91%) 177 | 176 / 1497 (11.76%) 210 | 134 / 1526 (8.78%) 154 |
| Oral candidiasis subjects affected / exposed occurrences (all) | 7 / 1493 (0.47%) 7 | 1 / 1497 (0.07%) 1 | 8 / 1526 (0.52%) 8 |
| Oral fungal infection subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Oral herpes subjects affected / exposed occurrences (all) | 3 / 1493 (0.20%) 3 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Orchitis subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Otitis externa subjects affected / exposed occurrences (all) | 5 / 1493 (0.33%) 5 | 3 / 1497 (0.20%) 3 | 3 / 1526 (0.20%) 3 |
| Otitis media subjects affected / exposed occurrences (all) | 95 / 1493 (6.36%) 120 | 99 / 1497 (6.61%) 117 | 116 / 1526 (7.60%) 143 |
| Otitis media acute subjects affected / exposed occurrences (all) | 46 / 1493 (3.08%) 55 | 49 / 1497 (3.27%) 60 | 57 / 1526 (3.74%) 65 |
| Parasitic gastroenteritis subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Paronychia subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 2 / 1526 (0.13%) 2 |
| Periorbital cellulitis | | | |

| | | | |
|--|-------------------|-------------------|-------------------|
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 50 / 1493 (3.35%) | 53 / 1497 (3.54%) | 55 / 1526 (3.60%) |
| occurrences (all) | 61 | 56 | 57 |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 2 | 1 | 1 |
| Pharyngotonsillitis | | | |
| subjects affected / exposed | 14 / 1493 (0.94%) | 15 / 1497 (1.00%) | 17 / 1526 (1.11%) |
| occurrences (all) | 15 | 16 | 17 |
| Pneumonia | | | |
| subjects affected / exposed | 5 / 1493 (0.33%) | 8 / 1497 (0.53%) | 9 / 1526 (0.59%) |
| occurrences (all) | 5 | 8 | 9 |
| Pneumonia mycoplasmal | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 1 | 1 |
| Pneumonia viral | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pseudocroup | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pyelonephritis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pyoderma | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory syncytial virus bronchiolitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory syncytial virus infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 4 / 1497 (0.27%) | 2 / 1526 (0.13%) |
| occurrences (all) | 1 | 4 | 2 |

| | | | |
|-----------------------------------|-------------------|-------------------|-------------------|
| Respiratory tract infection | | | |
| subjects affected / exposed | 24 / 1493 (1.61%) | 24 / 1497 (1.60%) | 22 / 1526 (1.44%) |
| occurrences (all) | 25 | 28 | 30 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 4 / 1493 (0.27%) | 9 / 1497 (0.60%) | 7 / 1526 (0.46%) |
| occurrences (all) | 5 | 10 | 11 |
| Rhinitis | | | |
| subjects affected / exposed | 37 / 1493 (2.48%) | 49 / 1497 (3.27%) | 30 / 1526 (1.97%) |
| occurrences (all) | 53 | 56 | 33 |
| Rhinovirus infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Roseola | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 3 / 1497 (0.20%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Salmonellosis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Scarlet fever | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Sinusitis | | | |
| subjects affected / exposed | 11 / 1493 (0.74%) | 10 / 1497 (0.67%) | 7 / 1526 (0.46%) |
| occurrences (all) | 12 | 10 | 7 |
| Sinusitis bacterial | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Skin bacterial infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Skin candida | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---------------------|---------------------|---------------------|
| Staphylococcal abscess | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Staphylococcal infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Streptococcal infection | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 1 / 1497 (0.07%) | 3 / 1526 (0.20%) |
| occurrences (all) | 2 | 1 | 3 |
| Superinfection bacterial | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Tonsillitis | | | |
| subjects affected / exposed | 34 / 1493 (2.28%) | 24 / 1497 (1.60%) | 34 / 1526 (2.23%) |
| occurrences (all) | 36 | 27 | 36 |
| Tonsillitis bacterial | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 0 / 1526 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tracheitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 3 / 1497 (0.20%) | 2 / 1526 (0.13%) |
| occurrences (all) | 1 | 3 | 2 |
| Tracheobronchitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 350 / 1493 (23.44%) | 354 / 1497 (23.65%) | 365 / 1526 (23.92%) |
| occurrences (all) | 475 | 473 | 485 |
| Upper respiratory tract infection bacterial | | | |

| | | | |
|---|-------------------|-------------------|-------------------|
| subjects affected / exposed | 2 / 1493 (0.13%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 4 / 1493 (0.27%) | 2 / 1497 (0.13%) | 4 / 1526 (0.26%) |
| occurrences (all) | 5 | 3 | 5 |
| Varicella | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 1 | 1 |
| Viral infection | | | |
| subjects affected / exposed | 45 / 1493 (3.01%) | 51 / 1497 (3.41%) | 57 / 1526 (3.74%) |
| occurrences (all) | 50 | 57 | 61 |
| Viral pharyngitis | | | |
| subjects affected / exposed | 5 / 1493 (0.33%) | 2 / 1497 (0.13%) | 3 / 1526 (0.20%) |
| occurrences (all) | 5 | 2 | 3 |
| Viral rash | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Viral rhinitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 1 / 1497 (0.07%) | 3 / 1526 (0.20%) |
| occurrences (all) | 0 | 1 | 3 |
| Viral tonsillitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 1 / 1497 (0.07%) | 1 / 1526 (0.07%) |
| occurrences (all) | 1 | 1 | 1 |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 1493 (0.13%) | 6 / 1497 (0.40%) | 11 / 1526 (0.72%) |
| occurrences (all) | 2 | 6 | 12 |
| Vulvitis | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vulvovaginitis | | | |
| subjects affected / exposed | 0 / 1493 (0.00%) | 0 / 1497 (0.00%) | 1 / 1526 (0.07%) |
| occurrences (all) | 0 | 0 | 1 |
| Wound infection | | | |
| subjects affected / exposed | 1 / 1493 (0.07%) | 0 / 1497 (0.00%) | 0 / 1526 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |

| | | | |
|--|-------------------------------|-------------------------------|-------------------------------|
| Decreased appetite subjects affected / exposed occurrences (all) | 571 / 1493 (38.25%) 575 | 593 / 1497 (39.61%) 595 | 593 / 1526 (38.86%) 593 |
| Dehydration subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 1 / 1497 (0.07%) 1 | 0 / 1526 (0.00%) 0 |
| Disaccharide metabolism disorder subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Failure to thrive subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 2 / 1526 (0.13%) 2 |
| Feeding disorder subjects affected / exposed occurrences (all) | 1 / 1493 (0.07%) 1 | 0 / 1497 (0.00%) 0 | 0 / 1526 (0.00%) 0 |
| Hyposideraemia subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 1 / 1526 (0.07%) 1 |
| Lactase deficiency subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 0 / 1497 (0.00%) 0 | 1 / 1526 (0.07%) 1 |
| Lactose intolerance subjects affected / exposed occurrences (all) | 0 / 1493 (0.00%) 0 | 1 / 1497 (0.07%) 1 | 2 / 1526 (0.13%) 2 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 17 February 2014 | <ul style="list-style-type: none">At CBER's request, the US non post dose 2 sub cohort was eliminated. This sub cohort was previously defined as any child enrolled in the US after the target enrollment of 1000 US children was met. These children would not have been required to have a blood sample taken post dose 2 as post dose 2 immunogenicity testing was only required in 1000 children. At CBER's request, the serologic response after each dose of both Merck's MMR-II and GSK's investigational vaccine will be evaluated in all US children. In the event that the pre-specified criteria for seroresponse are not met, U.S. children will be offered vaccination with MMR-II to assure protection from measles, mumps and rubella diseases.Vaccination against influenza and haemophilus influenza type B can be given at any time before, during, or after the study, including the day of study vaccination. This is to correct a prior exclusion criterion which stated that it could be given at any time during the study. The intent has always been to allow these vaccinations at any time regardless of whether or not it was before, during or after the study period.For other MMR US Phase III studies, CBER has requested that all conditions leading to non-routine medically attended visits be collected for the entire study in the eCRF. It has been clarified throughout the protocol that From Visit 1 (Day 0) to study end (Day 180), all medically attended events will be recorded in the eCRF. Subjects' routine 'well child' doctor visits will not be recorded in the eCRF. |
| 19 May 2015 | <ul style="list-style-type: none">Serological assays for the determination of antibodies against measles, rubella and varicella viruses will now be performed by a new 3rd party Contract Research Organization (CRO) named NEOMED-LABS Inc. Initially the testing was planned to be performed by GSK Biologicals' laboratory in Rixensart. The assays have been transferred to GSK Biologicals' laboratory in Laval. As of April 1st 2015, the GSK Biologicals' laboratory in Laval became part of Neomed. The only change between GSK Biologicals' laboratory in Laval and NEOMED-LABS Inc. is the name of the laboratory: assays and facilities remain the same.Due to a delay in the availability of serologic data for the mumps Plaque Reduction Neutralization Test (PRNT) data analysis for this study will be conducted as follows: Part 1 will include a summary of measles, mumps and rubella Enzyme-Linked Immunosorbent Assay (ELISA) results post dose 1 (Day 42) and post dose 2 (Day 84). Part 2 will include a full immunogenicity analysis for post dose 1 (Day 42) and post dose 2 (Day 84) including mumps PRNT results post dose 1, and all safety data. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported